IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE: IOT), a pioneer in the field of biofilm product development, is pleased to announce that its proprietary BEST™ (Biofilm Eradication Surface Test) assay for external efficacy testing was a key element in the recent FDA 510(k) market clearance of Teleflex Incorporated's ArrowEVOLUTION™, an advanced anti-microbial peripherally-inserted central catheter. Arrow EVOLUTION with Chlorag+ard™ technology provides a unique option to clinicians in their efforts to protect against central line-associated bloodstream infections, a major contributor to hospital acquired infections.

"Our recent project with Teleflex is yet another demonstration of Innovotech's expertise in microbial biofilms and its distinguished track record in meeting client's needs," said Ken Boutilier, President and CEO of Innovotech Inc. "Biofilms cause major problems in human health, from hospital-acquired infections (such as those caused by catheters) to food safety.

"FDA market clearance of the ArrowEVOLUTION™ catheter with Chlorag+ard™ technology enhances Teleflex's position as a leading global provider of medical technology products," said Barry McBride, Teleflex Chief Technology Officer. "Innovotech's sense of urgency, understanding of the requirements and their extensive commercial knowledge of biofilm microbiology were significant contributing factors in the development and execution of external efficacy testing for submission."

About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are responsible for a host of diseases both in human health and agriculture due to their inherent resistance to existing antibiotics and disinfectants. There are currently no antibiotics, disinfectants, diagnostics or regulatory standards designed specifically for biofilm-forming organisms.

Innovotech currently has two products in advanced stages of development: bioFILM PA™, the first diagnostic kit to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based chronic lung infections and Agress™, a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections.

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts: Innovotech Inc. Ken Boutilier President and CEO (780) 448-0585 ext. 221 (780) 424-0941 (FAX) ken.boutilier@innovotech.ca www.innovotech.ca